- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases
This study is looking at a new treatment called Newnorm for people with primary immunodeficiency. It's an injection under the skin. We want to see how well it prevents infections and if it's safe. It will also check how the body uses the medicine.
For: Human Normal ImmunoglobulinItaly · Slovakia · Hungary - Active not recruitingPHASE3
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
This study is looking at a new way to give an existing medicine, Newnorm, for people with primary immune deficiency. It's given under the skin. We want to check if it's safe, works well, and how the body uses it.
For: Primary Immune DeficiencyUnited States · Germany · Hungary